FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...
Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical ...
In a conversation with Pharmaceutical Executive, Nate Hill, Co-Founder & CEO of Strive Pharmacy, discussed the regulatory ...
When treating IBD, what are the restraints with JAK inhibitors? Christian Thienel: JAK inhibitors have been around for quite a while, and they are understood to be highly effective. The JAK-STAT ...
It has been an eventful weeks in pharma and biotech news so far in 2026. Here is a guide to every major story and what it ...
Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...
Nate Hill, co-founder & CEO, Strive, notes the key milestone to watch for during the remaining step in FDA's formal Category ...
Recently, Pharmaceutical Executive spoke with Christian Thienel, director at Back Bay Life Sciences, about the ongoing issues ...
Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
Pharmaceutical Executive recently spoke with Mark Cziraky, president of Carelon Research. The company just signed a deal with ...
Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results